Covered recipient · General Payments record
JIGAR SHAH
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$60,386.34
130 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Honoraria | $34,216.00 | 22 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $23,200.00 | 12 |
| Food and Beverage | $2,354.37 | 91 |
| Travel and Lodging | $615.97 | 5 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Horizon Therapeutics plc | $35,588.14 | 55 |
| GlaxoSmithKline, LLC. | $21,243.57 | 17 |
| AstraZeneca Pharmaceuticals LP | $2,606.89 | 4 |
| Amgen Inc. | $213.27 | 14 |
| AbbVie Inc. | $185.09 | 13 |
| UCB, Inc. | $126.30 | 7 |
| PFIZER INC. | $126.02 | 6 |
| Mallinckrodt Hospital Products Inc. | $105.14 | 4 |
| Novartis Pharmaceuticals Corporation | $68.90 | 3 |
| E.R. Squibb & Sons, L.L.C. | $36.00 | 2 |
| Kiniksa Pharmaceuticals, Ltd. | $23.10 | 1 |
| Ultragenyx Pharmaceutical Inc. | $18.71 | 1 |
| Teva Pharmaceuticals USA, Inc. | $17.01 | 1 |
| SANOFI-AVENTIS U.S. LLC | $15.51 | 1 |
| Radius Health, Inc. | $12.69 | 1 |
Page 3 of 3; records 101–130 of 130 matching records. This page contains 30 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JIGAR SHAH
NPI 1659508166 · CMS profile ID 347688
Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology
MARGATE, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–130 of 130 matching records. This page contains 30 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1659508166?year=2021&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JIGAR SHAH, NPI 1659508166, CMS profile ID 347688. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–130 of 130 matching records. This page contains 30 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659508166?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). JIGAR SHAH, NPI 1659508166, CMS profile ID 347688. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–130 of 130 matching records. This page contains 30 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659508166?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- JIGAR SHAH, NPI 1659508166, CMS profile ID 347688, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–130 of 130 matching records. This page contains 30 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1659508166?year=2021&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
130 matching records · $60,386.34 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–130 of 130.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AbbVie Inc. | $0.80 | 04/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796011329 | CMS |
| AbbVie Inc. | $5.32 | 04/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796011331 | CMS |
| GlaxoSmithKline, LLC. | $3,600.00 | 04/07/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802868575 | CMS |
| Horizon Therapeutics plc | $200.00 | 04/05/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797204785 | CMS |
| Teva Pharmaceuticals USA, Inc. | $17.01 | 04/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 839636367 | CMS |
| Horizon Therapeutics plc | $1,020.00 | 03/31/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797204783 | CMS |
| GlaxoSmithKline, LLC. | $125.00 | 03/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802877237 | CMS |
| Amgen Inc. | $20.75 | 03/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825417287 | CMS |
| AbbVie Inc. | $10.94 | 03/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796011327 | CMS |
| GlaxoSmithKline, LLC. | $1,200.00 | 03/09/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802990257 | CMS |
| PFIZER INC. | $23.70 | 03/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832651521 | CMS |
| UCB, Inc. | $27.97 | 03/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807304335 | CMS |
| Horizon Therapeutics plc | $8.28 | 02/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797204779 | CMS |
| GlaxoSmithKline, LLC. | $13.96 | 02/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802220935 | CMS |
| GlaxoSmithKline, LLC. | $3,600.00 | 02/16/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802884509 | CMS |
| Horizon Therapeutics plc | $1,020.00 | 02/13/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797204777 | CMS |
| UCB, Inc. | $17.30 | 02/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807307185 | CMS |
| Horizon Therapeutics plc | $1,020.00 | 02/08/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797204773 | CMS |
| GlaxoSmithKline, LLC. | $1,200.00 | 02/04/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 801658631 | CMS |
| Horizon Therapeutics plc | $1,020.00 | 02/04/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797204771 | CMS |
| PFIZER INC. | $24.80 | 02/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832594111 | CMS |
| PFIZER INC. | $7.73 | 02/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832851329 | CMS |
| Amgen Inc. | $21.40 | 01/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825417269 | CMS |
| GlaxoSmithKline, LLC. | $125.00 | 01/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802891397 | CMS |
| Novartis Pharmaceuticals Corporation | $36.20 | 01/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813249251 | CMS |
| Horizon Therapeutics plc | $1.00 | 01/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797204765 | CMS |
| Horizon Therapeutics plc | $7.16 | 01/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797204767 | CMS |
| PFIZER INC. | $19.53 | 01/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832729853 | CMS |
| GlaxoSmithKline, LLC. | $1,800.00 | 01/12/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 803037543 | CMS |
| AbbVie Inc. | $23.67 | 01/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796011325 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,296,842.30 | 71 |
| PY2024 | Recipient | $27,504.58 | 2 |
| PY2024 | Principal investigator | $995,618.72 | 76 |
| PY2023 | Principal investigator | $495,317.67 | 93 |
| PY2022 | Principal investigator | $548,956.32 | 82 |
| PY2021 | Recipient | $140.90 | 1 |
| PY2021 | Principal investigator | $420,026.19 | 24 |
| PY2020 | Recipient | $777.04 | 1 |
| PY2020 | Principal investigator | $55,128.00 | 3 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
71 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $7,575.00 | 12/11/2025 | Non-covered Recipient Entity CORAZON USA LLC | A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren s Disease (SjD) | No dispute reported | 06/30/2026 | 1202530126 |
| Principal investigator 1 | ABBVIE INC. | $6,885.55 | 12/08/2025 | Non-covered Recipient Entity CORAZON USA LLC | A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren s Disease (SjD) | No dispute reported | 06/30/2026 | 1202529640 |
| Principal investigator 1 | UCB SA | $16,250.00 | 12/08/2025 | Non-covered Recipient Entity CORAZON USA LLC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS | No dispute reported | 06/30/2026 | 1246658254 |
| Principal investigator 1 | ABBVIE INC. | $2,640.00 | 12/04/2025 | Non-covered Recipient Entity CORAZON USA LLC | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202527976 |
| Principal investigator 1 | ABBVIE INC. | $12,039.50 | 12/04/2025 | Non-covered Recipient Entity CORAZON USA LLC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202528786 |
| Principal investigator 1 | ABBVIE INC. | $989.51 | 12/04/2025 | Non-covered Recipient Entity CORAZON USA LLC | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202528806 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $2,500.00 | 12/03/2025 | Non-covered Recipient Entity Corazon USA LLC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431278 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,212.57 | 11/19/2025 | Non-covered Recipient Entity Corazon USA LLC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431272 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $240.61 | 11/19/2025 | Non-covered Recipient Entity Corazon USA LLC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431282 |
| Principal investigator 1 | ABBVIE INC. | $75.00 | 11/05/2025 | Non-covered Recipient Entity CORAZON USA LLC | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202522195 |
| Principal investigator 1 | ABBVIE INC. | $6,536.25 | 11/04/2025 | Non-covered Recipient Entity CORAZON USA LLC | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202520549 |
| Principal investigator 1 | ABBVIE INC. | $47,527.50 | 11/04/2025 | Non-covered Recipient Entity CORAZON USA LLC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202520551 |
| Principal investigator 1 | ARGENX US, INC. | $3,000.00 | 10/22/2025 | Non-covered Recipient Entity CORAZON USA LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237149253 |
| Principal investigator 1 | ARGENX US, INC. | $3,000.00 | 10/22/2025 | Non-covered Recipient Entity CORAZON USA LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237149259 |
| Principal investigator 1 | ARGENX US, INC. | $1,250.00 | 10/22/2025 | Non-covered Recipient Entity CORAZON USA LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237149264 |
| Principal investigator 1 | ARGENX US, INC. | $2,200.00 | 10/22/2025 | Non-covered Recipient Entity CORAZON USA LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237149269 |
| Principal investigator 1 | ARGENX US, INC. | $2,000.00 | 10/22/2025 | Non-covered Recipient Entity CORAZON USA LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237149273 |
| Principal investigator 1 | ARGENX US, INC. | $16,000.00 | 10/22/2025 | Non-covered Recipient Entity CORAZON USA LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237149278 |
| Principal investigator 1 | ARGENX US, INC. | $1,500.00 | 10/22/2025 | Non-covered Recipient Entity CORAZON USA LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237149283 |
| Principal investigator 1 | Amgen Inc. | $20,497.66 | 10/22/2025 | Non-covered Recipient Entity CORAZON USA, LLC | A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis | No dispute reported | 06/30/2026 | 1246640525 |
| Principal investigator 1 | ABBVIE INC. | $10,323.75 | 10/09/2025 | Non-covered Recipient Entity CORAZON USA LLC | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202515327 |
| Principal investigator 1 | Aurinia Pharma U.S., Inc. | $6,600.00 | 10/08/2025 | Non-covered Recipient Entity Corazon USA, LLC | LUPKYNIS Registry Study | No dispute reported | 06/30/2026 | 1243931074 |
| Principal investigator 1 | GENZYME CORPORATION | $28,921.00 | 10/06/2025 | Non-covered Recipient Entity Corazon Usa Llc Dba Life Clinical Trials | A randomized, double-blind, Phase 3, 52-week study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active iGG4-related disease. | No dispute reported | 06/30/2026 | 1226140114 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,259.84 | 10/02/2025 | Non-covered Recipient Entity Corazon USA LLC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431276 |
| Principal investigator 1 | ABBVIE INC. | $2,640.00 | 09/03/2025 | Non-covered Recipient Entity CORAZON USA LLC | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202507169 |
| Principal investigator 1 | ARGENX US, INC. | $35.80 | 09/03/2025 | Non-covered Recipient Entity CORAZON USA LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237149286 |
| Principal investigator 1 | ARGENX US, INC. | $668.50 | 09/03/2025 | Non-covered Recipient Entity CORAZON USA LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237149290 |
| Principal investigator 1 | ARGENX US, INC. | $159.00 | 09/03/2025 | Non-covered Recipient Entity CORAZON USA LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237149294 |
| Principal investigator 1 | ARGENX US, INC. | $6.65 | 09/03/2025 | Non-covered Recipient Entity CORAZON USA LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237149300 |
| Principal investigator 1 | ARGENX US, INC. | $103.50 | 09/03/2025 | Non-covered Recipient Entity CORAZON USA LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237149304 |
| Principal investigator 1 | ARGENX US, INC. | $75.20 | 09/03/2025 | Non-covered Recipient Entity CORAZON USA LLC | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237149307 |
| Principal investigator 1 | Amgen Inc. | $333.35 | 08/26/2025 | Non-covered Recipient Entity LIFE CLINICAL TRIALS | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246643562 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $19,735.00 | 08/06/2025 | Non-covered Recipient Entity CORAZON USA, LLC | A Multicenter,Randomized,Double blind,Placebo controlled,Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Systemic Sclerosis | No dispute reported | 06/30/2026 | 1185544605 |
| Principal investigator 1 | ABBVIE INC. | $12,660.00 | 08/05/2025 | Non-covered Recipient Entity CORAZON USA LLC | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202501178 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $21,297.33 | 07/25/2025 | Non-covered Recipient Entity KERLO RESEARCH | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246433209 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $19,735.00 | 07/23/2025 | Non-covered Recipient Entity CORAZON USA, LLC | A Multicenter, Parallel-group, Double-blind, 2-Arm, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Added to Standard of Care in Adult Participants with Polymyositis | No dispute reported | 06/30/2026 | 1185544607 |
| Principal investigator 1 | Eli Lilly and Company | $25,604.00 | 07/23/2025 | Non-covered Recipient Entity CORAZON USA LLC | A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187878827 |
| Principal investigator 1 | ABBVIE INC. | $44,695.00 | 07/02/2025 | Non-covered Recipient Entity CORAZON USA LLC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202496575 |
| Principal investigator 1 | ABBVIE INC. | $23,145.00 | 07/02/2025 | Non-covered Recipient Entity CORAZON USA LLC | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202496577 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $7,082.10 | 07/02/2025 | Non-covered Recipient Entity KERLO RESEARCH | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246433198 |
| Principal investigator 1 | ABBVIE INC. | $17,000.00 | 06/25/2025 | Non-covered Recipient Entity CORAZON USA LLC | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202492845 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,212.57 | 06/25/2025 | Non-covered Recipient Entity Corazon USA LLC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431270 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,950.00 | 06/17/2025 | Non-covered Recipient Entity CORAZON USA LLC | A Two-year, Phase III Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Evaluate the Safety, Efficacy, and Tolerability of 300 mg s.c. Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis | No dispute reported | 06/30/2026 | 1190311205 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,905.12 | 06/11/2025 | Non-covered Recipient Entity KERLO RESEARCH | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246433236 |
| Principal investigator 1 | ABBVIE INC. | $12,795.00 | 06/03/2025 | Non-covered Recipient Entity CORAZON USA LLC | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202488313 |
| Principal investigator 1 | ABBVIE INC. | $100.00 | 06/03/2025 | Non-covered Recipient Entity CORAZON USA LLC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202488317 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $8,250.00 | 06/02/2025 | Non-covered Recipient Entity KERLO RESEARCH | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246433245 |
| Principal investigator 1 | ABBVIE INC. | $20,160.00 | 05/06/2025 | Non-covered Recipient Entity CORAZON USA LLC | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202482073 |
| Principal investigator 1 | Amgen Inc. | $112,510.66 | 04/28/2025 | Non-covered Recipient Entity CORAZON USA, LLC | A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants | No dispute reported | 06/30/2026 | 1246640527 |
| Principal investigator 1 | Eli Lilly and Company | $21,262.00 | 04/28/2025 | Non-covered Recipient Entity CORAZON USA LLC | A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE | No dispute reported | 06/30/2026 | 1187878517 |
| Principal investigator 1 | ABBVIE INC. | $433.17 | 04/08/2025 | Non-covered Recipient Entity CORAZON USA LLC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202474969 |
| Principal investigator 1 | ABBVIE INC. | $3,787.50 | 04/03/2025 | Non-covered Recipient Entity CORAZON USA LLC | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202469978 |
| Principal investigator 1 | ABBVIE INC. | $5,662.00 | 04/03/2025 | Non-covered Recipient Entity CORAZON USA LLC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202473735 |
| Principal investigator 1 | Aurinia Pharma U.S., Inc. | $1,755.00 | 03/26/2025 | Non-covered Recipient Entity Corazon USA, LLC | LUPKYNIS Registry Study | No dispute reported | 06/30/2026 | 1243931064 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $4,462.69 | 03/14/2025 | Non-covered Recipient Entity KERLO RESEARCH | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246433217 |
| Principal investigator 1 | Aurinia Pharma U.S., Inc. | $2,632.50 | 03/12/2025 | Non-covered Recipient Entity Corazon USA, LLC | LUPKYNIS Registry Study | No dispute reported | 06/30/2026 | 1243930900 |
| Principal investigator 1 | ABBVIE INC. | $14,988.75 | 03/07/2025 | Non-covered Recipient Entity CORAZON USA LLC | M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202459671 |
| Principal investigator 1 | ABBVIE INC. | $4,910.00 | 03/06/2025 | Non-covered Recipient Entity CORAZON USA LLC | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202456789 |
| Principal investigator 1 | Eli Lilly and Company | $4,250.00 | 03/05/2025 | Non-covered Recipient Entity CORAZON USA LLC | TALTZ PSA OBSERVATIONAL STUDY | No dispute reported | 06/30/2026 | 1187878749 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $172.08 | 03/05/2025 | Non-covered Recipient Entity Corazon USA LLC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431280 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,733.69 | 03/03/2025 | Non-covered Recipient Entity Corazon USA LLC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431274 |
| Principal investigator 1 | ABBVIE INC. | $21,504.50 | 02/06/2025 | Non-covered Recipient Entity CORAZON USA LLC | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202449777 |
| Principal investigator 1 | ABBVIE INC. | $11,876.25 | 02/06/2025 | Non-covered Recipient Entity CORAZON USA LLC | M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202449781 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,708.18 | 02/05/2025 | Non-covered Recipient Entity KERLO RESEARCH | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246433222 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $29,600.00 | 02/04/2025 | Non-covered Recipient Entity Corazon Usa Llc Dba Life Clinical Trials | A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1226139968 |
| Principal investigator 1 | Eli Lilly and Company | $2,540.34 | 01/23/2025 | Non-covered Recipient Entity CORAZON USA LLC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | No dispute reported | 06/30/2026 | 1187880377 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $38,279.65 | 01/21/2025 | Non-covered Recipient Entity Life Clinical Trials | A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2) | No dispute reported | 06/30/2026 | 1235996189 |
| Principal investigator 1 | Eli Lilly and Company | $123,618.00 | 01/21/2025 | Non-covered Recipient Entity CORAZON USA LLC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | No dispute reported | 06/30/2026 | 1187881416 |
| Principal investigator 1 | Amgen Inc. | $1,413,938.48 | 01/13/2025 | Non-covered Recipient Entity LIFE CLINICAL TRIALS | A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants | No dispute reported | 06/30/2026 | 1246643570 |
| Principal investigator 1 | Amgen Inc. | $23,340.00 | 01/03/2025 | Non-covered Recipient Entity LIFE CLINICAL TRIALS | A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis | No dispute reported | 06/30/2026 | 1246643566 |
| Principal investigator 1 | ABBVIE INC. | $2,505.00 | 01/02/2025 | Non-covered Recipient Entity CORAZON USA LLC | M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202436118 |